Stockreport

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomali...

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF -- Financing to support advancement of two next-generation PI3K a pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program [Read more]